- Home
- ADEA vs TARS Comparison
ADEA vs TARS Comparison
Compare ADEA & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADEA
- TARS
- Stock Information
- Founded
- ADEA 1990
- TARS 2016
- Country
- ADEA United States
- TARS United States
- Employees
- ADEA N/A
- TARS N/A
- Industry
- ADEA Computer Software: Prepackaged Software
- TARS Medicinal Chemicals and Botanical Products
- Sector
- ADEA Technology
- TARS Health Care
- Exchange
- ADEA Nasdaq
- TARS Nasdaq
- Market Cap
- ADEA 1.6B
- TARS 1.7B
- IPO Year
- ADEA N/A
- TARS 2020
- Fundamental
- Price
- ADEA $15.52
- TARS $57.25
- Analyst Decision
- ADEA Strong Buy
- TARS Strong Buy
- Analyst Count
- ADEA 4
- TARS 7
- Target Price
- ADEA $19.50
- TARS $67.14
- AVG Volume (30 Days)
- ADEA 551.8K
- TARS 737.4K
- Earning Date
- ADEA 08-05-2025
- TARS 08-06-2025
- Dividend Yield
- ADEA 1.37%
- TARS N/A
- EPS Growth
- ADEA 80.44
- TARS N/A
- EPS
- ADEA 0.74
- TARS N/A
- Revenue
- ADEA $378,674,000.00
- TARS $295,521,000.00
- Revenue This Year
- ADEA $10.01
- TARS $122.94
- Revenue Next Year
- ADEA $4.42
- TARS $44.14
- P/E Ratio
- ADEA $20.98
- TARS N/A
- Revenue Growth
- ADEA 5.47
- TARS 254.45
- 52 Week Low
- ADEA $10.59
- TARS $25.14
- 52 Week High
- ADEA $17.46
- TARS $57.60
- Technical
- Relative Strength Index (RSI)
- ADEA 66.17
- TARS 79.79
- Support Level
- ADEA $14.40
- TARS $53.15
- Resistance Level
- ADEA $15.39
- TARS $55.17
- Average True Range (ATR)
- ADEA 0.58
- TARS 2.03
- MACD
- ADEA 0.13
- TARS 0.89
- Stochastic Oscillator
- ADEA 95.29
- TARS 97.95
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.